Atrial Flutter
📧 Sign up to get email alerts when something new happens for Atrial Flutter.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2017-04-11Clinical Trial Update: Ablating Atrial Tachycardias Occuring During Ablation of Complex Fractionated Electrograms in Persistent AF [NA]
A completed clinical trial evaluating ablation strategies for atrial tachycardias occurring during ablation of complex fractionated electrog…
-
CLINICAL_TRIALS trial_result · 2017-03-07Clinical Trial Update: Dipole Density Right Atrial Mapping and Assessment of Therapy In Cavotricuspid Isthmus Flutter [NA]
The clinical trial evaluating dipole density right atrial mapping to guide therapy for cavotricuspid isthmus flutter has completed, accordin…
-
FDA approval · 2017-01-23FDA Approved: CARDIZEM CD — Supplemental Application (Bausch Health US LLC)
The FDA approved a supplemental application for Cardizem CD (diltiazem hydrochloride) from Bausch Health US LLC under NDA 020062, allowing c…
-
FDA approval · 2016-12-01FDA Approved: LANOXIN — Supplemental Application (Advanz Pharma (US) Corp.)
The FDA approved a supplemental application for LANOXIN (digoxin) submitted by Advanz Pharma US Corp.
-
FDA approval · 2016-12-01FDA Approved: DIGOXIN — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
The FDA approved a supplemental application for Digoxin from Hikma Pharmaceuticals USA Inc. The action reflects approved product changes und…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2016-11-18FDA Approved: VERAPAMIL HYDROCHLORIDE — Supplemental Application (Wilshire Pharmaceuticals, Inc.)
FDA approved a supplemental application for verapamil hydrochloride from Wilshire Pharmaceuticals, Inc., updating the existing NDA.
-
FDA label_change · 2016-11-18FDA Approved: CARDIZEM LA — Supplemental Application (Bausch Health US LLC)
FDA approved a supplemental application for Cardizem LA (diltiazem hydrochloride extended-release) submitted by Bausch Health US LLC.
-
FDA approval · 2016-11-18FDA Approved: VERAPAMIL HYDROCHLORIDE — Supplemental Application (Teva Pharmaceuticals Inc)
FDA approved a supplemental application for Verapamil hydrochloride from Teva Pharmaceuticals Inc.
-
FDA approval · 2016-11-18FDA Approved: DILTIAZEM HYDROCHLORIDE — Supplemental Application (Oceanside Pharmaceuticals)
FDA approved Oceanside Pharmaceuticals' supplemental application for diltiazem hydrochloride. The approval confirms a modification to the pr…
-
FDA approval · 2016-11-18FDA Approved: CARDIZEM CD — Supplemental Application (Bausch Health US LLC)
FDA approved a supplemental application for Cardizem CD (diltiazem hydrochloride) submitted by Bausch Health US LLC.
-
FDA approval · 2016-11-08FDA Approved: MATZIM LA — Supplemental Application (Actavis Pharma, Inc.)
The FDA approved a supplemental application for MATZIM LA, a diltiazem hydrochloride product from Actavis Pharma, Inc.
-
FDA approval · 2016-10-21FDA Approved: SOTALOL — Original Application (UNICHEM PHARMACEUTICALS (USA), INC.)
FDA approved an original ANDA for sotalol hydrochloride (Sotalol) from Unichem Pharmaceuticals (USA), Inc., enabling generic access to this …
-
CLINICAL_TRIALS trial_result · 2016-10-19Clinical Trial Update: Atrial Flutter Ablation in a Real World Population
Clinical trial update on atrial flutter ablation in a real-world population; no results are reported in the available snippet.
-
CLINICAL_TRIALS trial_result · 2016-10-17Clinical Trial Update: Safety and Efficacy of Vanoxerine for the Conversion of Subjects With Recent Onset Atrial Fibrillation or Flutter to Normal Sinus Rhythm [Phase 3]
A Phase 3 study evaluating vanoxerine for converting recent-onset atrial fibrillation or flutter to normal sinus rhythm; the trial was termi…
-
CLINICAL_TRIALS trial_result · 2016-10-06Clinical Trial Update: Cryoablation as Standard Treatment of Atrial Flutter [NA]
A trial evaluating cryoablation as standard treatment for atrial flutter has completed.
-
CLINICAL_TRIALS trial_result · 2016-10-03Clinical Trial Update: Efficacy of Transcatheter Radiofrequency Ablation of Atrial Flutter With Standard Irrigated Catheter With Flexible Tip [NA]
This clinical trial update reports the efficacy of transcatheter radiofrequency ablation with a flexible-tip irrigated catheter for atrial f…
-
CLINICAL_TRIALS trial_result · 2016-07-25Clinical Trial Update: Exploring the Efficacy of Once Daily Oral Rivaroxaban for Treatment of Thrombus in Left Atrial/Left Atrial Appendage in Subjects With Nonvalvular Atrial Fibrillation or Atrial Flutter [Phase 3]
Phase 3 trial update of once-daily rivaroxaban for treating thrombus in the left atrium/left atrial appendage in nonvalvular atrial fibrilla…
-
FDA label_change · 2016-06-29FDA Approved: CARDIZEM CD — Supplemental Application (Bausch Health US LLC)
FDA has approved a supplemental application for Cardizem CD (diltiazem hydrochloride) filed by Bausch Health US LLC under NDA 020062.
-
FDA approval · 2016-06-06FDA Approved: DOFETILIDE — Original Application (Dr. Reddy's Labratories Inc.)
FDA approved Dr. Reddy's Laboratories' original application for dofetilide, enabling a generic version of the antiarrhythmic. It is indicate…
-
FDA approval · 2016-05-11FDA Approved: PROPAFENONE HYDROCHLORIDE — Original Application (Aurobindo Pharma Limited)
FDA approved the original application for propafenone hydrochloride (generic) manufactured by Aurobindo Pharma Limited.
-
FDA approval · 2016-05-10FDA Approved: BETAPACE — Supplemental Application (Legacy Pharma USA, Inc.)
The FDA approved a supplemental application for BETAPACE (sotalol hydrochloride) filed by Legacy Pharma USA, Inc.
-
CLINICAL_TRIALS trial_result · 2016-04-20Clinical Trial Update: Clarification of Optimal Anticoagulation Through Genetics [Phase 3]
A Phase 3 trial evaluating genotype-guided warfarin dosing to optimize anticoagulation has completed.
-
FDA label_change · 2016-04-08FDA Approved: VERAPAMIL HYDROCHLORIDE — Supplemental Application (EXELA PHARMA SCIENCES, LLC)
FDA approved a supplemental application for verapamil hydrochloride, resulting in changes to its labeling.
-
FDA approval · 2016-04-07FDA Approved: ESMOLOL HYDROCHLORIDE IN WATER — Original Application (WG Critical Care, LLC)
FDA approved Esmolol hydrochloride in water as a new drug product under NDA205703 (Original Application) from WG Critical Care, LLC.
-
CLINICAL_TRIALS trial_result · 2016-03-22Clinical Trial Update: Determination of Catheter Contact by Evaluation of Microelectrode Near-Field Signals [NA]
Completed clinical trial evaluating catheter contact determination using near-field microelectrode signals during cardiac ablation.